Search research articles
Contact Us
Filters
Showing results (21-30 of 65) with videos related to
Page
of 7
Sort By:
Clinical Pharmacology and Therapeutics
|
April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
Arnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 5, 2017
Ulcerative Colitis Treatment Patterns and Cost of Care
Kyle D Null, Yihua Xu, Margaret K Pasquale, et al.
Therapeutic Advances in Gastroenterology
|
December 12, 2022
Modified Mayo score <i>versus</i> Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
William J Sandborn, Bruce E Sands, Séverine Vermeire, et al.
Digestive Diseases and Sciences
|
August 21, 2020
Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials
Remo Panaccione, John D Isaacs, Lea Ann Chen, et al.
The Patient
|
November 6, 2022
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
David P Hudesman, Joana Torres, Leonardo Salese, et al.
Digestive Diseases and Sciences
|
October 10, 2020
Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials
Remo Panaccione, John D Isaacs, Lea Ann Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 31, 2020
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis
William J Sandborn, Laurent Peyrin-Biroulet, Daniel Quirk, et al.
Digestive Diseases and Sciences
|
February 4, 2023
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
Gary R Lichtenstein, Benjamin L Cohen, Leonardo Salese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 8, 2021
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status
William J Sandborn, Laurent Peyrin-Biroulet, Ala I Sharara, et al.
Alimentary Pharmacology & Therapeutics
|
January 22, 2019
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study
Julián Panés, Geert R D'Haens, Peter D R Higgins, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 65) with videos related to
Sort By:
Page
of 7
Clinical Pharmacology and Therapeutics
|
April 5, 2022
Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
Arnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 5, 2017
Ulcerative Colitis Treatment Patterns and Cost of Care
Kyle D Null, Yihua Xu, Margaret K Pasquale, et al.
Therapeutic Advances in Gastroenterology
|
December 12, 2022
Modified Mayo score <i>versus</i> Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
William J Sandborn, Bruce E Sands, Séverine Vermeire, et al.
Digestive Diseases and Sciences
|
August 21, 2020
Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials
Remo Panaccione, John D Isaacs, Lea Ann Chen, et al.
The Patient
|
November 6, 2022
Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
David P Hudesman, Joana Torres, Leonardo Salese, et al.
Digestive Diseases and Sciences
|
October 10, 2020
Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials
Remo Panaccione, John D Isaacs, Lea Ann Chen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 31, 2020
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis
William J Sandborn, Laurent Peyrin-Biroulet, Daniel Quirk, et al.
Digestive Diseases and Sciences
|
February 4, 2023
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis
Gary R Lichtenstein, Benjamin L Cohen, Leonardo Salese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
March 8, 2021
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status
William J Sandborn, Laurent Peyrin-Biroulet, Ala I Sharara, et al.
Alimentary Pharmacology & Therapeutics
|
January 22, 2019
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study
Julián Panés, Geert R D'Haens, Peter D R Higgins, et al.
Page
of 7